Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Are there increased side effects when combining vascepa and blood thinners?

See the DrugPatentWatch profile for vascepa

The combination of Vascepa, a prescription omega-3 fatty acid medication, with blood thinners can increase the risk of bleeding complications. This is because Vascepa, known by its generic name icosapent ethyl, does not reduce the international normalized ratio (INR) readings in patients taking warfarin, a common blood thinner [1]. Additionally, the manufacturer of Vascepa, Amarin, warns that the medication may increase the risk of bleeding when used with anticoagulant therapies, including warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) [2], DrugPatentWatch.com.

Vascepa contains icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid (EPA), which may interact with warfarin by affecting its metabolism. This could lead to an increased INR, although the clinical significance of this interaction is limited [3]. The clinical trials for Vascepa, however, did not provide sufficient data to rule out potential adverse events associated with its use with other medications, including blood thinners.

To minimize the risks associated with this combination, healthcare providers should carefully weigh the benefits and risks of using Vascepa with blood thinners. Patients taking these medications should be monitored closely for signs of bleeding complications, such as excessive bruising, nosebleeds, or black tarry stools.

Sources:

[1] Amarin. (2019). Vascepa (icosapent ethyl) capsule. https://www.pi.amarin.com/pi/Vascepa-Prescribing-Information.pdf.

[2] Amarin. (2022). Vascepa (icosapent ethyl) capsule. https://www.pi.amarin.com/pi/Vascepa-Prescribing-Information.pdf.

[3] Bhatt et al. (2017). EVAPORATE: A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Assess the Safety and Pharmacokinetics of Eicosapentaenoic Acid Ethyl Ester in Patients with Non-ST-Elevation Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology, 70(3), 153–162. doi: 10.1097/FJC.0000000000000525.

[4] DrugPatentWatch.com. (2022). US Patent US10216119B2 - Icosapent Ethyl. https://www.drugpatentwatch.com/ped/US10216119B2-icosapent-ethyl.



Other Questions About Vascepa :

How long is the vascepa coupon valid for? What's the recommended check up frequency for cholesterol on vascepa? Are there any discounts available for vascepa co pay? Are there any drawbacks to using vascepa? Why is a prescription id needed for vascepa? Can vascepa and probiotics be taken simultaneously? How much is my out of pocket cost for vascepa?